[Skip to Navigation]
February 28, 2019

Association of Crystalline Retinopathy With Anastrozole

Author Affiliations
  • 1Montefiore Medical Center/Albert Einstein College of Medicine, Department of Ophthalmology and Visual Sciences, Bronx, New York
  • 2Brooklyn Eye Center, Brooklyn, New York
  • 3Jacobi Medical Center, Department of Surgery (Ophthalmology), Bronx, New York
JAMA Ophthalmol. 2019;137(5):581-582. doi:10.1001/jamaophthalmol.2019.0064

Anastrozole is an oral nonsteroidal aromatase inhibitor used to treat advanced breast cancer in postmenopausal women by preventing the conversion of adrenal androgens into estrogen.1 This contrasts with the better-known antiestrogen drug tamoxifen, which blocks estrogen from binding to its receptor in breast tissue. Reported ophthalmologic adverse effects of anastrozole include retinal hemorrhages, bilateral optic disc swelling, vitreoretinal traction, dry eye, and possibly uveitis and macular edema.1 This case report describes a patient receiving anastrozole therapy who was found to have crystalline retinopathy.

Add or change institution